Department of Urology, the First Affiliated Hospital of Xi\'an Jiaotong University, Xi\'an, P.R. China.
Oncology Research Lab, Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, P.R. China.
Curr Med Chem. 2022;29(41):6276-6287. doi: 10.2174/0929867329666220613125000.
In recent years, the incidence of erectile dysfunction (ED) has continued to rise worldwide. Since pharmacotherapy is still the most common and effective method for the treatment of ED at present, many methods and drugs have been designed or developed for the treatment of ED. Oral phosphodiesterase-5 inhibitors and androgen supplement therapy are currently the common therapeutics for ED; however, some patients have poor responses to these drugs because of the multiple pathogenic mechanisms of ED. Researchers are trying to find other treatment ways. On the one hand, many new strategies and concepts, such as targeted therapy, are also integrated into clinical or preclinical research; on the other hand, some combined therapies that have synergistic effects with a reduced dose of a single drug and less adverse effects are also developed. This review article summarized the efficacy of the latest first-line, second-line drugs and adjuvant therapies for the treatment of ED, as well as the application of comprehensive treatments, which will help doctors not only deeply understand the mechanism of ED but select the suitable therapeutics for those patients.
近年来，全球范围内勃起功能障碍（ED）的发病率持续上升。由于目前药物治疗仍然是 ED 治疗的最常用和最有效的方法，因此已经设计或开发了许多方法和药物来治疗 ED。口服磷酸二酯酶-5 抑制剂和雄激素补充疗法是目前 ED 的常见治疗方法；然而，由于 ED 的多种发病机制，一些患者对这些药物的反应不佳。研究人员正在寻找其他治疗方法。一方面，许多新的策略和概念，如靶向治疗，也被纳入临床或临床前研究；另一方面，一些联合治疗方法，与减少单一药物的剂量和减少不良反应具有协同作用，也在开发中。本文综述了最新一线、二线药物和辅助治疗 ED 的疗效，以及综合治疗的应用，这将有助于医生不仅深入了解 ED 的机制，而且为患者选择合适的治疗方法。
